Novartis Ag (NVSEF) Debt to Equity (2015 - 2025)

Novartis Ag has disclosed Debt to Equity across 11 years of filings, most recently posting $0.62 for Q4 2025.

• Debt to Equity for Q4 2025 came in at $0.62, up 24.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.62 (up 24.87% YoY), and the FY2025 annual result was $0.62, up 24.87% from the prior year.
• Debt to Equity came in at $0.62 for Q4 2025 at Novartis Ag, up from $0.5 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.62 in Q4 2025 to a low of $0.41 in Q4 2023.
• The 5-year median for Debt to Equity is $0.44 (2022), against an average of $0.48.
• Across the five-year window, Debt to Equity soared 102.14% in 2021 and decreased 7.44% in 2023, its largest moves.
• Novartis Ag's Debt to Equity stood at $0.43 in 2021, then climbed by 2.32% to $0.44 in 2022, then declined by 7.44% to $0.41 in 2023, then gained by 22.33% to $0.5 in 2024, then gained by 24.87% to $0.62 in 2025.
• The last three Debt to Equity figures came in at $0.62 (Q4 2025), $0.5 (Q4 2024), and $0.41 (Q4 2023), per Business Quant data.